[PDF] Top 20 Analysis of Treatment Effect of Lamivudine, Adefovir Add-on Therapy in Patients with Lamivudine Resistant Chronic B-viral Hepatitis
Has 10000 "Analysis of Treatment Effect of Lamivudine, Adefovir Add-on Therapy in Patients with Lamivudine Resistant Chronic B-viral Hepatitis" found on our website. Below are the top 20 most common "Analysis of Treatment Effect of Lamivudine, Adefovir Add-on Therapy in Patients with Lamivudine Resistant Chronic B-viral Hepatitis".
Evaluating the efficacy of switching from lamivudine plus adefovir to tenofovir disoproxil fumarate monotherapy in lamivudine-resistant stable hepatitis B patients
... apy in CHB. Goals of antiviral treatment are achievement of a sustained suppression of HBV replication and a decrease in morbidity and mortality related to ...antiviral ... See full document
12
Evaluation of methods for monitoring drug resistance in chronic hepatitis B patients during lamivudine therapy based on mass spectrometry and reverse hybridization
... performance of the RFMP assay for detecting mutations associated with lamivudine resistance was compared with that of LiPA for 60 chronically HBV- infected patients who had shown ... See full document
9
Association between single nucleotide polymorphisms in deoxycytidine kinase and lamivudine monotherapy response among patients with chronic hepatitis B
... recently, lamivudine has been considered as first-line therapy for individuals with non-cirrhotic and cirrhotic liver ...efficacy of lamivudine is limited by the development of ... See full document
67
Is tenofovir and entecavir combination therapy still the optimal treatment for chronic hepatitis B patients with prior suboptimal response?
... College of Medicine, Korea It is well-known that consistently high hepatitis B virus (HBV) DNA levels increase the risk of fibrosis progression and hepatocel- lular carcinoma (HCC) development ... See full document
3
Oral antiviral agents for treatment of chronic hepatitis B
... goal of antiviral therapy for chronic hepatitis B virus (HBV) infection is to eliminate or suppress HBV with the aim of preventing the devastating complications of ... See full document
8
Factors affecting initial virologic response and emergence of resistant mutants after adefovir treatment in lamivudine resistant chronic hepatitis B patients
... HBeAg 양성인 환자가 64명(84. 2%)이었고 간경변이 동반된 환자가 20명(26. 3%) 이었다. B.연구 방법 혈청학적 검사는 HBeAg,anti -HBe,ALT,AST,HBV DNA를 아데포비 어 투여 직전과 투여 중 3개월 간격으로 측정하였다.또한 투여 전 YMDD 변이 와 precore 변이(G1896A)존재 여부를 측정하였고,아데포비어 내성 돌연변이 ... See full document
29
Low efficacy of entecavir therapy in adefovir-refractory hepatitis B patients with prior lamivudine resistance.
... ng therapy , genotypi c anal ysi s of rtM204 sequences,and LAM was swi tched to ADV ...LAM therapy. None of the pati ent had co-i nfecti ons(HCV, HIV) or other concomi tantl i verdi ... See full document
30
Management of entecavir-resistant chronic hepatitis B with adefovir-based combination therapies
... total of 50 CHB patients with genotypic ETV resistance, who subsequently received rescue ADV- based combination therapy for more than 12 mo at 13 medical centers in South Korea between ... See full document
10
were treated with lamivudine. The duration of lamivudine therapy was from 6 to 64 months (mean 20 months).
... The Korean Journal of Gastroenterology: Vol. 42, No. 4, 2003 310 HBeAg의 음전이나 혈청전환으로 하여도 재발률에 차이가 없어 치료 종료 시점으로 할 수 없으며 추후 다른 인자나 다른 방법을 통해 종료 시점을 찾는 노력이 필요하겠다. 치 료 반응 후 치료를 중단한 환자에서 라미부딘 총 사용 기간 이 12개월 미만 투여군과 ... See full document
10
Efficacy of entecavir verses lamivudine prophylaxis in preventing hepatitis B virus reactivation in patients with allogeneic stem cell transplant
... Sixty patients, thirty in each group who received LVD or ETV prophylaxis were included in the ...duration of prophylaxis of each drugs and clinical and virological follow up post ... See full document
1
Daclatasvir and asunaprevir combination therapy for patients with chronic hepatitis C virus genotype 1b infection in real world
... combination therapy showed high rates of RVR, ETR, and SVR12 when used to treat patients with chronic HCV genotype 1b infec- tion in real ...combination therapy ... See full document
8
Liver stiffness measurement for the diagnosis of hepatic fibrosis in patients with chronic viral hepatitis
... i b b br r ro o oS S Sc c ca a an n n ® ® ® 을 을 을 이 이 이용 용 용한 한 한 간 간 간탄 탄 탄력 력 력도 도 도 측 측 측정 정 정 Fi broScan ® (EchoSens ® , Pari s, France)은 저주파수의 탄성파를 주사하는 피스톤에 초음파 변환기가 더하여진 것으로,조직을 통과하는 탄성파의 속도를 초음파 영상을 ... See full document
30
Rapid normalization of alanine aminotransferase predicts viral response during combined peginterferon and ribavirin treatment in chronic hepatitis C patients
... during treatment in genotype 1 group might be considered as useful response factor in clinical practice, for patients with initial abnormal ALT ...course of CHC treatment, ... See full document
7
Durability after discontinuation of nucleos(t)ide therapy in chronic HBeAg negative hepatitis patients
... 것을 목표로 하였다. 방법: 대상환자는 총 45명으로, NUC 치료시작후 HBV DNA가 음성화되고, 최소 18개월 간 음성이 지속되어 NUC treatment를 중단한 E항원음성 만성간염 환자를 대상으로 하 였고, NUC의 종류는 각각 entecavir 25명, lamivudine 14명, adefovir 6명이었습니다. ... See full document
23
Impact of ribavirin dose reduction during treatment in chronic hepatitis C genotype 1 patients
... impact of dose reduction during the first several weeks of treatment on SVR has also been assessed in patients with prior nonresponders to interferon-based therapy ... See full document
4
라미부딘 치료로 HBeAg 혈청전환 후 재발한 만성B형간염 환자에서 유전자의 변이 =Genetic change of full-length hepatitis B virus in relapsed patients with chronic hepatitis B after lamivudine-induced HBeAg seroconveraion
... 라미부딘 등 항바이러스 치료 후 바이러스가 비증식하다 다시 재발하는 정우，두 가지 가능성이 제시된다 첫째는 田V 가 특정 유전자의 부위에 변이가 생기고 이로 인해 田V의 증식능이 증가 하는 경우이다 현재까지 田V 의 증식에 관여하는 것으로 알려진 부위는 BCP 영역에서 특히， 1762 번 염기서열이 A-)T 및 1764 번 염기서열이 G-)A 로 치환되는 돌연변이 (AI762T/GI764A) ... See full document
7
An integrated analysis of elbasvir/grazoprevir in Korean patients with hepatitis C virus genotype 1b infection
... This analysis had several limitations. Most patients in this study were treatment-naive and HCV mono-infected; caution when ex- trapolating these findings to other patients groups, such ... See full document
8
Prediction models of hepatocellular carcinoma development in chronic hepatitis B patients
... Chronic hepatitis B virus (HBV) infection is the main cause of cirrhosis, hepatic failure, and hepatocellular carcinoma (HCC) globally [1] ...Of chronic HBV carriers, approximately 15%-40% develop ... See full document
9
Long term outcome of antiviral therapy in patients with hepatitis B associated decompensated cirrhosis
... definitions in various clinical settings, because pattern of prescribing antiviral agent might be quite different depending on the clinical ...133 patients were not enough to validate for 7166 ... See full document
13
Serum markers for predicting significant necroinflammatory activity in patients with chronic hepatitis B
... marker of the inflammatory response driven by HBV ...levels of serum PIINP have been found in active liver disease such as chronic active hepatitis and active cirrhosis ...In ... See full document
30
관련 주제